United Therapeutics
United Therapeutics is a biotechnology company and public benefit corporation dedicated to developing novel pharmaceutical therapies for rare diseases and innovative organ manufacturing technologies. The company primarily focuses on treating pulmonary arterial hypertension (PAH) and other chronic lung diseases while engineering an unlimited supply of transplantable organs. Their core value proposition lies in providing life-sustaining treatments for patients with unmet medical needs through drug-device combinations and advanced regenerative medicine.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Pulmonary Hypertension and Rare Disease Therapies
primaryThis segment focuses on the development and commercialization of pharmaceutical products and delivery systems for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It includes a portfolio of prostacyclin analogues and PDE-5 inhibitors delivered through various inhalation, oral, and injectable methods.
Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Adcirca, Remunity Pump, RemunityPRO Pump
Specialty pharmaceutical distributors, International pharmaceutical distributors, Hospitals, Specialty pharmacies
Oncology
moderateThis segment involves the marketing of biologic therapies for rare pediatric cancers. The primary product is a chimeric monoclonal antibody used for high-risk neuroblastoma.
Unituxin
Specialty pharmaceutical distributors, Pediatric oncology centers
Organ Manufacturing and Transplantation
minorA research and development-heavy segment focused on addressing the shortage of transplantable organs through xenotransplantation, regenerative medicine, and organ bio-printing. It aims to create manufactured organs such as kidneys and hearts using gene-edited porcine models.
UKidney, UHeart, UThymoKidney, GalSafe
Transplant centers, Research institutions
Segment Financials
Nebulized Tyvaso — Total revenues
View metricNebulized Tyvaso — Cost of Sales
View metricTyvaso DPI — Royalty as a percentage of net sales
View metricUnituxin — Total revenues
View metricUnituxin — Cost of Sales
View metricUnituxin — Royalty as a percentage of net sales
View metricOrenitram — Total revenues
View metricBusiness Overview
Competitive Position
A leading player in the PAH market with a dominant position in treprostinil-based therapies and a pioneer in the emerging field of xenotransplantation.
Geographies
United States, Japan, Europe, Canada
Customer Segments
Specialty Distributors, Healthcare Providers, Rare Disease Patients
Upstream Dependencies
Contract manufacturers, Active pharmaceutical ingredient suppliers, Medical device component manufacturers, Gene-editing technology providers
Downstream Customers
Specialty pharmaceutical distributors, Hospitals, Specialty pharmacies, End-stage organ failure patients
Competitors & Partners
Competitors
Partners
Mannkind
MNKD
Licensor of dry powder formulation and Dreamboat inhalation device technology for Tyvaso DPI
DEKA Research & Development Corp.
Development and license partner for the Remunity Pump system
Eli Lilly
LLY
Licensor of commercial rights for Adcirca in the United States
Sanner GmbH
Acquired Gilero LLC, a contract manufacturer for Remodulin pump cartridges
ICU Medical
ICUI
Manufacturer of infusion pumps used for Remodulin administration
United Therapeutics FAQ
Common questions about United Therapeutics
United Therapeutics is a biotechnology company and public benefit corporation dedicated to developing novel pharmaceutical therapies for rare diseases and innovative organ manufacturing technologies. The company primarily focuses on treating pulmonary arterial hypertension (PAH) and other chronic lung diseases while engineering an unlimited supply of transplantable organs. Their core value proposition lies in providing life-sustaining treatments for patients with unmet medical needs through drug-device combinations and advanced regenerative medicine.
United Therapeutics (UTHR) has a market capitalization of $24.1B and trades on NASDAQ.
United Therapeutics generated $3.2B in trailing twelve-month revenue with net income of $1.3B, representing a net margin of 40.6%. Gross margin stands at 86.6%, with free cash flow of $1.0B. These figures are based on the Q1 2026 filing.
United Therapeutics's key competitors include Insmed, Inc., Merck & Co., Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
United Therapeutics has approximately 1,168 employees.